WO2014191222A1 - Predictive biomarker for cancer therapy - Google Patents
Predictive biomarker for cancer therapy Download PDFInfo
- Publication number
- WO2014191222A1 WO2014191222A1 PCT/EP2014/059995 EP2014059995W WO2014191222A1 WO 2014191222 A1 WO2014191222 A1 WO 2014191222A1 EP 2014059995 W EP2014059995 W EP 2014059995W WO 2014191222 A1 WO2014191222 A1 WO 2014191222A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- dna
- cells
- tlr
- activated
- Prior art date
Links
- 239000000092 prognostic biomarker Substances 0.000 title description 5
- 238000011275 oncology therapy Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 108020004414 DNA Proteins 0.000 claims description 55
- 239000000556 agonist Substances 0.000 claims description 34
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 29
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims description 6
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 150000004705 aldimines Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000002082 metal nanoparticle Substances 0.000 claims description 2
- 239000002923 metal particle Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 abstract description 2
- 239000000090 biomarker Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 26
- 210000001616 monocyte Anatomy 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 11
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 11
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 101100269308 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PFS1 gene Proteins 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100273742 Mus musculus Cd69 gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- -1 TLR-3 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates generally to the identification of cancer patients as to whether they will respond to specific therapies. More particularly the invention relates to a method and DNA construct for identifying responders to a therapy involving immune activating DNA constructs, as well as to a DNA construct intended to treat cancer patients individually characterized as potential responders prior to the start of a treatment with said construct.
- Biomarkers are substances found in blood or other body fluids, in tissues or as receptors on cells that signal the presence or absence of a condition or disease, like cancer for instance. Biomarkers can be differentiated into predictive, prognostic and pharmacodynamics biomarkers.
- Predictive biomarkers are used to assess the probability that a patient will respond to or benefit from a particular treatment.
- Prognostic biomarkers allow for the classification of tumours with regard to their aggressive potential to guide a decision of whom to treat or how aggressively to treat.
- Pharmacodynamic biomarkers measure the near-term treatment effects of a drug on the tumour and might be used to guide dose selection during clinical development of a new anti-cancer drug.
- Targeted therapies are treatments that work on a molecular level to stop a cancer from growing or spreading.
- therapies are usually related to the use of very aggressive drugs, there is a need for tools allowing to predict whether a patient will respond to a targeted therapy or not.
- Another object of the invention is the immune activating DNA itself, which can be used in such a method, i.e. to treat a patient identified as responder prior to the start of treatment
- the present invention provides a method for predicting or monitoring whether a patient suffering from cancer or an autoimmune disease will respond or responds to treatment with a TLR-9 agonist by determining the frequency of activated natural killer T (NKT) cells. It is preferred to determine the cluster of differentiation or cluster of designation (CD) molecules CD3+/CD56+/CD69+ for immunophenotyping of activated NKT cells. The ratio of activated NKT cells of the whole NKT cell population may also be determined in order to assess the probability whether a patient will respond to a treatment with a TLR-9 agonist.
- NKT natural killer T
- the TLR-9 agonist is a DNA construct comprising at least one sequence motif NVCGNV, wherein N ! N 2 and N 3 N 4 is any combination of A, C, T, and G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine
- a responder to the treatment with the TLR-9 agonist shall have a frequency of at least 3 % of activated NKT cells of the whole NKT cell population.
- an induction therapy with a non-DNA drug may be performed.
- Such a therapy comprises chemotherapy with or without angiogenesis inhibitor or the use of antibodies.
- a further object of the present disclosure is a TLR-9 agonist for use in a method of treatment of cancer, characterised in that the patient has elevated levels of activated NKT cells.
- the used TLR-9 agonist comprises at least a DNA construct comprising at least one sequence motif N 1 N 2 CGN 3 N 4 , wherein N J N 2 and N 3 N 4 is any combination of A, C, T, and G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine
- the agonist may further be characterised by N J N 2 being an element selected from the group comprising GT, GG, GA, AT or AA, N 3 N 4 being an element selected from the group comprising CT or TT.
- the agonist may comprise DNA that is a linear open-chained DNA construct com- prising single or double-stranded DNA or is a linear double-stranded DNA construct, which comprises at least one end with a single stranded loop. Instead of using loops to protect the ends of the linear double strands at least one L-DNA nucleotide may be used as part of the DNA double strand.
- the sequence motif N ! N 2 CGN 3 N 4 shall be located within a single-stranded and/or a double-stranded region of the DNA sequence.
- At least one nucleotide of a DNA TLR-9 agonist is modified with a functional group selected from the group com- prising carboxyl, amine, amide, aldimine, ketal, acetal, ester, ether, disulfide, thiol and aldehyde groups.
- the agonist comprising a DNA construct can be linked to a compound selected from the group comprising peptides, proteins, carbohydrates, antibodies, lipids, micelles, vesicles, synthetic molecules, polymers, micro projectiles, metal particles, nanoparticles, or a solid phase.
- the agonist comprising a DNA construct can be part of a pharmaceutical composition, wherein the pharmaceutical composition can be a vaccine.
- Another object of the present disclosure is a kit for predicting or monitoring whether a patient suffering from cancer or auto immune disease will respond or responds to treatment with a TLR-9 agonist comprising means for detecting and quantifying the frequency of activated NKT cells of the whole NKT cell population.
- the TLR-9 agonist may comprise a DNA construct comprising at least one sequence motif N 1 N 2 CGN 3 N 4 , wherein N J N 2 and N 3 N 4 is any combination of A, C, T, and G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine
- Figure 1 ROC curves in verum patients for activated NKT cells.
- Figure 2 Activated NKT cells versus sensitivity and specificity.
- Figure 3 a: Kaplan-Meier plot in biomarker positive patients for verum and placebo; b: Kaplan-Meier curve for the biomarker negative patients in both the verum and placebo arm.
- Figure 4 a: Kaplan-Meier plot of biomarker positive patients versus bi- omarker negative patients in the verum arm; b: Kaplan-Meier plot of the placebo group for biomarker positive and negative patients.
- MGN1703 designates a DNA construct of a covalently closed partially self-complementary DNA chain having a double stranded stem and single stranded terminal loops bearing unmethylated CG motifs.
- a "stem” shall be understood as a DNA double strand formed by base pairing either within the same DNA molecule (which is then partially self-complementary) or within different DNA molecules (which are partially or completely complementary).
- Intramolecular base pairing designates base pairing within the same molecules, and base pairing between different DNA molecules is termed as intermolecular base-pairing.
- a "loop" within the meaning of the present disclosure shall be understood as an unpaired, single-stranded region either within or at the end of a stem structure.
- a “hairpin” is a distinct combination of a stem and a loop, which occurs when two self-complementary re- gions of the same DNA molecule hybridize to form a stem with an unpaired loop.
- a "dumbbell-shape” describes a linear DNA construct with hairpins at both ends flanking a stem region.
- a “linear DNA construct” within the context of the present disclosure describes a linear dumbbell-shaped DNA construct comprising single stranded loops at both ends of a double stranded DNA stem.
- Immunomodulation refers to immune activation and immunosuppression.
- Immune activation means preferentially that effector cells of the immune system are activated in order to proliferate, migrate, differentiate or become active in any other form.
- B cell proliferation for instance can be induced without co-stimulatory signals by immune activating DNA molecules, which normally require a co-stimulatory signal from helper T-cells.
- Immunosuppression on the other hand shall be understood as reducing the activation or efficacy of the immune system.
- Immunosuppression is generally deliberately induced to prevent for instance the rejection of a transplanted organ, to treat graft-versus-host disease after a bone marrow transplant, or for the treatment of autoimmune diseases such as, for ex- ample, rheumatoid arthritis or Crohn's disease.
- immunomodulation may also refer to influencing the nature or the character of an immune reaction, either by affecting an immune reaction, which is still developing or maturing or by modulating the character of an established immune reaction.
- the term conveyorvaccination used in this disclosure refers to the administration of antigenic material (a vaccine) to produce immunity to a disease.
- Vaccines can prevent or ameliorate the effects of infection by many pathogens such as viruses, fungi, protozoan parasites, bacteria but also of allergic diseases and asthma, as well as of tumors.
- Vaccines typically con- tain one or more adjuvants, e.g. immune activating nucleic acids, used to boost the immune response.
- Vaccination is generally considered to be the most effective and cost-effective method of preventing infectious and other diseases.
- the material administered can, for example, be live but weakened forms of path- ogens (bacteria or viruses), killed or inactivated forms of these pathogens, purified material such as proteins, nucleic acids encoding antigens, or cells such as tumor cells or dendritic cells.
- DNA vaccination has recently been developed. DNA vaccination works by insertion (and expression, triggering immune system recognition) of DNA encoding antigens into human or animal cells. Some cells of the immune system that recognize the proteins ex- pressed will mount an attack against these proteins and against cells expressing them.
- DNA vaccines One advantage of DNA vaccines is that they are very easy to produce and store.
- DNA vaccines have a number of advantages over conventional vaccines, including the ability to induce a wider range of immune response types.
- Vaccination can be used as a prophylactic approach, leading to immunity against the antigen in the vaccinated, healthy individual upon exposure to the antigen.
- a therapeutic vaccination can cause an improved response of the immune system of the vaccinated, diseased individual, by guiding the immune system of the individual towards the an- tigens. Both prophylactic and therapeutic vaccination can be applied to humans as well as animals.
- cancer comprises cancerous diseases or a tumor being treated or pre- vented that is selected from the group comprising, but not limited to, mammary carcinomas, melanoma, skin neoplasms, lymphoma, leukemia, gastrointestinal tumors, including colon carcinomas, stomach carcinomas, pancreas carcinomas, colon cancer, small intestine cancer, ovarial carcinomas, cervical carcinomas, lung cancer, prostate cancer, kidney cell carcinomas and/or liver metastases.
- Autoimmune diseases comprise rheumatoid arthritis, Crohn's disease, systemic lupus (SLE), autoimmune thyroiditis, Hashimoto's thyroiditis, multiple sclerosis, Graves' disease, myasthenia gravis, celiac disease and Addison's disease.
- TLRs toll-like receptors
- TLRs are part of the innate immune system.
- TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-related molecular patterns, such as proteins, lipid structures, sacharidic structures, and certain nucleic acids.
- Synthetic agonists for several TLRs, including TLR-3, TLR-4, TLR-7, TLR-8, and TLR-9, have been or are being developed for the treatment of cancer, generally with the intention to activate the immune system in the presence of tumours.
- TLR-9 recognizes the presence of unmethylated CG-containing DNA sequences, which are typically found in bacteria, but practically never in human genomic DNA.
- dumbbell-shaped DNA molecules are surprisingly suitable for the induction of an immune response.
- a dumbbell-shape DNA construct having unmethylated CG motifs in the single stranded terminal loops was used.
- monocytes activated monocytes 1 , activated monocytes 2, B-Cells, activated B-cells, T-cells, activated T-cells, natural killer (NK)-cells, activated NK-cells, NKT-cells, activated NKT- cells, plasmacytoid dendritic cells (pDCs), activated pDCs, myeloid dendritic cells (mDCs), and activated mDCs.
- monocytes activated monocytes 1 , activated monocytes 2, B-Cells, activated B-cells, T-cells, activated T-cells, natural killer (NK)-cells, activated NK-cells, NKT-cells, activated NKT- cells, plasmacytoid dendritic cells (pDCs), activated pDCs, myeloid dendritic cells (mDCs), and activated mDCs.
- Table 2 summarizes the context of cell types, CDs and the determined frequencies.
- Table 2 Relation of cell types, CDs and determined frequencies
- NK-cells CD3- / CD56+ all PBMCs activated NK-cells CD3- / CD56+ / CD69+ all natural killer cells
- NKT cells CD3+ / CD56+ all PBMCs activated NKT cells CD3+ / CD56+ / CD69+ all NKT cells plasmacytoid dendritic cells Linl- / CD 123+ / HLA- all PBMCs
- a receiver operating characteristic (ROC) curve shows the performance of a binary classifier system as its discrimination threshold is varied. ROC curves are created by plotting the fraction of true positives out of the positives versus the frac- tion of false positives out of the negatives at various threshold settings. The true positives are also designated as sensitivity and the false positives is one minus the specificity or true negative rate.
- ROC analysis is used in medicine, radiology, biometrics, and other areas for many decades and is increasingly used in machine learning and data mining research.
- biomarkers it can be used to study the study whether a potential biomarker can have clinical validity, i.e., whether it can be used for predictive purposes.
- a successful diagnostic test or biomarker will result in a curve that bends above the diagonal while an unsuccessful test will mirror the diagonal, or fall below it.
- a ROC curve provides information whether a diagnostic test is successful or not.
- ROC curves in verum patients for activated NKT cells were established (figure 1). The area under the curve was determined to be 0.71 , which is a clear indication of the reliability of the biomarker.
- the Youden-index which can be used to determine an optimum cut-off value for the test's readout, shows an optimum at cut-off at 3.08% activated NKT cells.
- Figure 2 shows activated NKT cells versus sensitivity and specificity.
- FIG. 3a shows a Kaplan-Meier plot in biomarker positive patients for verum and placebo (solid line: patients treated with MGN1703; dotted line: patients treated with placebo). It is obvious that the survival probability within the biomarker positive group is surprisingly related to the application of the TLR-9 agonist.
- Figure 3b shows a Kaplan-Meier curve for the biomarker negative patients in both the verum and placebo arm. It is obvious that the time of progression free survival is clearly shorter within this verum group as compared to the biomarker positive verum patients (comp. fig. 3a).
- Figure 4a shows a Kaplan-Meier plot of biomarker positive patients versus biomarker negative patients, only from the verum treatment arm (solid line: biomarker positive patients; dotted line: biomarker negative patients).
- solid line biomarker positive patients
- dotted line biomarker negative patients
- Figure 4b shows a Kaplan-Meier plot of the placebo group for biomarker positive and negative patients (solid line: biomarker positive patients; dotted line: biomarker negative patients). It is obvious that both groups show a more or less identical progression free survival as they were only treated with placebo. Clearly, the biomarker is suitable for assessing whether a patient is a responder to the treatment with a TLR-9 agonist or not. Further, the placebo group shows that the biomarker is not related to effects caused by the overall health status of a patient.
- the present invention provides new predictive biomarker for responder to a cancer treatment with a TLR-9 agonist, especially a covalently closed partially self-complementary DNA chain having a double stranded stem an single stranded terminal loops bearing un- methylated CG motifs.
- the determination of the frequencies of activated NKT cells (CD3+/CD56+/Cd69+) at baseline allows assessing the probability whether a patient is a re- sponder to treatment with the DNA construct or not.
- the patients with responder-like characteristics behave the same way as non-responders did, showing that the prolonged progression-free survival time of the biomarker positive verum patients is in fact due to the applicability of the biomarkers for the selected therapy, not just a better overall health or any non-specific effect.
- FACS Fluorescence activated cell sorting
- Cells were stained with the following combination of monoclonal antibodies: Anti- Lineage marker-FITC, (antibody cocktail containing antibodies directed against CD3, CD 14, CD16, CD19, CD20, CD56); Anti-CD 123 -PE; Anti-HLA-DR-PerCP; Anti-CD40-APC; PDC were gated as: lineage negative, HLA-DR positive, CD123 positive cells. Within the PDC population CD40 was used as activation marker.
- Anti- Lineage marker-FITC antibody cocktail containing antibodies directed against CD3, CD 14, CD16, CD19, CD20, CD56
- Anti-CD 123 -PE Anti-HLA-DR-PerCP
- Anti-CD40-APC Anti-CD40-APC
- PDC were gated as: lineage negative, HLA-DR positive, CD123 positive cells.
- CD40 was used as activation marker.
- NK cells were gated as: CD3 negative, CD56 positive cells
- NK-T cells were gated as: CD3 positive, CD56 positive cells
- T cells were gated as: CD3 positive, CD56 negative [0071] CD69 was used as activation marker for all 3 populations. [0072] CD86 expression of myeloid dendritic cells (MDC):
- Cells were stained with the following combination of monoclonal antibodies: Anti- Lineage marker-FITC, (antibody cocktail containing antibodies directed against CD3, CD 14, CD16, CD19, CD20, CD56); Anti-CDl lc-PE; Anti-HLA-DR-PerCP ; Anti-CD86-APC
- MDC were gated as: lineage negative, HLA-DR positive, CD1 lc positive cells.
- CD86 Within the MDC population CD86 was used as activation marker.
- CD86 expression of B cells and monocytes CD 169 expression of monocytes
- B cells were gated as CD 19 positive cells. Within the B cell population CD86 was used as activation marker.
- Monocytes were gated as CD 14 positive cells. Within the monocyte population CD86 and CD 169 were used as activation markers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480024805.8A CN105247365B (en) | 2013-05-30 | 2014-05-15 | Predictability biomarker use for cancer treatment |
RU2015150739A RU2672358C2 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
US14/891,869 US10006032B2 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
PL14725114T PL3004875T3 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
KR1020157029934A KR101937442B1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
DK14725114.4T DK3004875T3 (en) | 2013-05-30 | 2014-05-15 | PREDICTIVE BIOMARKER FOR CANCER THERAPY |
AU2014273400A AU2014273400B2 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
BR112015029852A BR112015029852A2 (en) | 2013-05-30 | 2014-05-15 | method for predicting or monitoring whether a patient suffering from cancer or an autoimmune disease will respond or respond to treatment with a tlr-9 agonist, tlr-9 agonist for use in a cancer treatment method, and a kit to predict or monitor if a patient suffering from cancer or autoimmune disease will respond or respond to treatment with a tlr-9 agonist |
MX2015016305A MX365512B (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy. |
CA2907980A CA2907980A1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
JP2016515715A JP6441320B2 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarkers for cancer treatment |
ES14725114T ES2795929T3 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
EP14725114.4A EP3004875B1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
ZA2015/06813A ZA201506813B (en) | 2013-05-30 | 2015-09-15 | Predictive biomarker for cancer therapy |
IL242551A IL242551A (en) | 2013-05-30 | 2015-11-11 | Predictive biomarker for cancer therapy |
HK16104519.6A HK1216779A1 (en) | 2013-05-30 | 2016-04-20 | Predictive biomarker for cancer therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1309657.3 | 2013-05-30 | ||
GB1309657.3A GB2514591A (en) | 2013-05-30 | 2013-05-30 | Predictive biomarker for cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014191222A1 true WO2014191222A1 (en) | 2014-12-04 |
Family
ID=48805478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/059995 WO2014191222A1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
Country Status (18)
Country | Link |
---|---|
US (1) | US10006032B2 (en) |
EP (1) | EP3004875B1 (en) |
JP (1) | JP6441320B2 (en) |
KR (1) | KR101937442B1 (en) |
CN (2) | CN105247365B (en) |
AU (1) | AU2014273400B2 (en) |
BR (1) | BR112015029852A2 (en) |
CA (1) | CA2907980A1 (en) |
DK (1) | DK3004875T3 (en) |
ES (1) | ES2795929T3 (en) |
GB (1) | GB2514591A (en) |
HK (1) | HK1216779A1 (en) |
IL (1) | IL242551A (en) |
MX (1) | MX365512B (en) |
PL (1) | PL3004875T3 (en) |
RU (1) | RU2672358C2 (en) |
WO (1) | WO2014191222A1 (en) |
ZA (1) | ZA201506813B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
US11578331B2 (en) | 2015-09-09 | 2023-02-14 | Gilead Sciences, Inc. | Combination comprising immunostimulatory oligonucleotides |
US11583581B2 (en) | 2015-09-21 | 2023-02-21 | Gilead Sciences, Inc. | Methods of treating a retroviral infection |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102290205B1 (en) | 2014-06-04 | 2021-08-20 | 엑시큐어, 인크. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
CN111278509A (en) * | 2017-08-31 | 2020-06-12 | 莫洛根股份公司 | TLR-9 agonists for modulating tumor microenvironment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010055340A1 (en) * | 2008-11-12 | 2010-05-20 | Ludwig Institute For Cancer Research | Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
WO2006015560A1 (en) * | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunomodulating agent used in conjunction with chemotherapy |
EP1922545A1 (en) * | 2005-09-08 | 2008-05-21 | Mologen AG | Functional in vitro immunoassay |
EP2079305A4 (en) * | 2006-12-12 | 2010-01-27 | Idera Pharmaceuticals Inc | Synthetic agonists of tlr9 |
EP2112930B1 (en) * | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
CN102864151B (en) * | 2007-08-01 | 2015-07-08 | 艾德拉药物股份有限公司 | Novel synthetic agonists of tlr9 |
CN101821412A (en) * | 2007-08-15 | 2010-09-01 | 艾德拉药物股份有限公司 | TOLL sample receptor modulators |
DK2219672T3 (en) * | 2007-11-09 | 2016-05-17 | Peregrine Pharmaceuticals Inc | The anti-VEGF antibody compositions and methods |
EP2073009A1 (en) * | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
AU2009241645B2 (en) | 2008-05-02 | 2014-07-17 | Blink Therapeutics Limited | Products and methods for stimulating an immune response |
WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
JP5705836B2 (en) * | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Modulators for HER2 signaling in gastric cancer patients expressing HER2 |
MX340363B (en) * | 2010-11-19 | 2016-07-06 | Idera Pharmaceuticals Inc | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response. |
GB201021867D0 (en) * | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
PT2744826T (en) * | 2011-08-16 | 2022-05-19 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a purine analog |
EP2682750A1 (en) * | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
-
2013
- 2013-05-30 GB GB1309657.3A patent/GB2514591A/en not_active Withdrawn
-
2014
- 2014-05-15 ES ES14725114T patent/ES2795929T3/en active Active
- 2014-05-15 DK DK14725114.4T patent/DK3004875T3/en active
- 2014-05-15 EP EP14725114.4A patent/EP3004875B1/en active Active
- 2014-05-15 WO PCT/EP2014/059995 patent/WO2014191222A1/en active Application Filing
- 2014-05-15 CN CN201480024805.8A patent/CN105247365B/en not_active Expired - Fee Related
- 2014-05-15 CN CN201910417409.6A patent/CN110201156A/en active Pending
- 2014-05-15 US US14/891,869 patent/US10006032B2/en active Active
- 2014-05-15 KR KR1020157029934A patent/KR101937442B1/en active IP Right Grant
- 2014-05-15 MX MX2015016305A patent/MX365512B/en active IP Right Grant
- 2014-05-15 RU RU2015150739A patent/RU2672358C2/en not_active Application Discontinuation
- 2014-05-15 JP JP2016515715A patent/JP6441320B2/en not_active Expired - Fee Related
- 2014-05-15 AU AU2014273400A patent/AU2014273400B2/en not_active Ceased
- 2014-05-15 BR BR112015029852A patent/BR112015029852A2/en not_active Application Discontinuation
- 2014-05-15 CA CA2907980A patent/CA2907980A1/en not_active Abandoned
- 2014-05-15 PL PL14725114T patent/PL3004875T3/en unknown
-
2015
- 2015-09-15 ZA ZA2015/06813A patent/ZA201506813B/en unknown
- 2015-11-11 IL IL242551A patent/IL242551A/en active IP Right Grant
-
2016
- 2016-04-20 HK HK16104519.6A patent/HK1216779A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010055340A1 (en) * | 2008-11-12 | 2010-05-20 | Ludwig Institute For Cancer Research | Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer |
Non-Patent Citations (6)
Title |
---|
ANONYMOUS: "A novel iNKT-mediated vaccine maneuver overcomes PD-1-mediated T cell exhaustion in cancer -- Varghese et al. 188 (1001): 165.13 -- The Journal of Immunology", 1 January 2012 (2012-01-01), XP055131252, Retrieved from the Internet <URL:http://www.jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/165.13> [retrieved on 20140723] * |
ANONYMOUS: "Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). -- Riera-Knorrenschild et al. 31 (15): 3643 -- ASCO Meeting Abstracts", 20 May 2013 (2013-05-20), XP055131313, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3643> [retrieved on 20140723] * |
H.-J. SCHMOLL ET AL: "O-0012 * UPDATED RESULTS OF THE RANDOMIZED PHASE 2 IMPACT TRIAL: MAINTENANCE WITH TLR-9 AGONIST MGN1703 VS PLACEBO IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC)", ANNALS OF ONCOLOGY, vol. 24, no. suppl 4, 1 June 2013 (2013-06-01), pages iv16 - iv17, XP055131314, ISSN: 0923-7534, DOI: 10.1093/annonc/mdt201.12 * |
HANS-JOACHIM SCHMOLL ET AL: "Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 10 May 2014 (2014-05-10), XP055131369, ISSN: 0171-5216, DOI: 10.1007/s00432-014-1682-7 * |
J. VAS ET AL: "Regulatory Roles for NKT Cell Ligands in Environmentally Induced Autoimmunity", THE JOURNAL OF IMMUNOLOGY, vol. 181, no. 10, 3 November 2008 (2008-11-03), pages 6779 - 6788, XP055131246, ISSN: 0022-1767, DOI: 10.4049/jimmunol.181.10.6779 * |
MONTOYA C J ET AL: "Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 120, no. 2, 1 August 2006 (2006-08-01), pages 138 - 146, XP024941265, ISSN: 1521-6616, [retrieved on 20060801], DOI: 10.1016/J.CLIM.2006.02.008 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11578331B2 (en) | 2015-09-09 | 2023-02-14 | Gilead Sciences, Inc. | Combination comprising immunostimulatory oligonucleotides |
US11583581B2 (en) | 2015-09-21 | 2023-02-21 | Gilead Sciences, Inc. | Methods of treating a retroviral infection |
EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
WO2018193137A1 (en) | 2017-04-22 | 2018-10-25 | Mologen Ag | Biomarker for small cell lung cancer therapy |
CN110914428A (en) * | 2017-04-22 | 2020-03-24 | 莫洛根股份公司 | Biomarkers for small cell lung cancer therapy |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
Also Published As
Publication number | Publication date |
---|---|
GB201309657D0 (en) | 2013-07-17 |
GB2514591A (en) | 2014-12-03 |
CN105247365A (en) | 2016-01-13 |
JP2016526164A (en) | 2016-09-01 |
ES2795929T3 (en) | 2020-11-25 |
CN105247365B (en) | 2019-06-18 |
AU2014273400A1 (en) | 2015-10-08 |
BR112015029852A2 (en) | 2017-07-25 |
KR101937442B1 (en) | 2019-01-11 |
DK3004875T3 (en) | 2020-06-08 |
CA2907980A1 (en) | 2014-12-04 |
ZA201506813B (en) | 2017-01-25 |
RU2015150739A (en) | 2017-07-06 |
MX2015016305A (en) | 2016-03-21 |
MX365512B (en) | 2019-06-05 |
PL3004875T3 (en) | 2020-11-16 |
RU2672358C2 (en) | 2018-11-14 |
HK1216779A1 (en) | 2016-12-02 |
EP3004875B1 (en) | 2020-03-04 |
CN110201156A (en) | 2019-09-06 |
US20160115479A1 (en) | 2016-04-28 |
EP3004875A1 (en) | 2016-04-13 |
US10006032B2 (en) | 2018-06-26 |
JP6441320B2 (en) | 2018-12-19 |
KR20150129860A (en) | 2015-11-20 |
IL242551A (en) | 2017-07-31 |
AU2014273400B2 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10006032B2 (en) | Predictive biomarker for cancer therapy | |
Droemann et al. | Human lung cancer cells express functionally active Toll-like receptor 9 | |
JP6247253B2 (en) | Leukemia stem cell marker | |
Pashenkov et al. | Phase II trial of a toll-like receptor 9–activating oligonucleotide in patients with metastatic melanoma | |
Krug et al. | Toll‐like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL‐12 | |
Weide et al. | Results of the first phase I/II clinical vaccination trial with direct injection of mRNA | |
Fűri et al. | Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects | |
Schuh et al. | Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement | |
JP2020517665A (en) | Biomarkers for the treatment of small cell lung cancer | |
EP2012772A1 (en) | Reducing cancer cell invasion using an inhibitor of toll like receptor signaling | |
US20210155933A1 (en) | Tlr-9 agonists for modulation of tumor microenvironment | |
Karbach et al. | Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies | |
EP3491387A1 (en) | Methods of treatement of cancer disease by targetting tumor associated macrophage | |
TW201823471A (en) | Methods of treating patients with a retinoic acid receptor-[alpha] agonist and an anti-CD38 antibody | |
Xu et al. | Toll-like receptor 9 ligands increase type I interferon induced B-cell activating factor expression in chronic rhinosinusitis with nasal polyposis | |
Ren et al. | Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients | |
JP2024521514A (en) | Sequential innate and adaptive immune modulation for cancer treatment | |
Kurtinović | Exploring the tumor microenvironment to improve immunotherapy for bladder cancer | |
Abdulmajed | Identification of Tumour Associated Antigens as Potential Targets for the Immunotherapy of B-cell Chronic Lymphocytic Leukaemia (B-CLL) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14725114 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2907980 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014273400 Country of ref document: AU Date of ref document: 20140515 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20157029934 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014725114 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 242551 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14891869 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/016305 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016515715 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015029852 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015150739 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015029852 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151127 |